Categories
Change Password!
Reset Password!
Indobufen is a safe and effective substitute for aspirin in DAPT following PCI in elderly ACS patients, offering comparable cardiovascular protection with improved gastrointestinal tolerability.
In a study led by Wenbo Dai et al., indobufen (antiplatelet agent) provided efficacy and safety outcomes comparable to aspirin when combined with clopidogrel in elderly acute coronary syndrome (ACS) patients post-percutaneous coronary intervention (PCI). The findings highlight indobufen’s comparable cardiovascular protection with fewer gastrointestinal (GI) side effects, addressing a long-standing clinical need in this high-risk population.
In this single-center, retrospective analysis, elderly ACS patients who underwent PCI were categorized based on their antiplatelet regimen:
The key outcome was the Net Adverse Clinical Event (NACE) at one year. It is a composite of myocardial infarction, all-cause mortality, stroke, target lesion revascularization, and major bleeding (Bleeding Academic Research Consortium [BARC] types 2, 3, or 5). A total of 2,087 patients were included, with 348 receiving indobufen-based DAPT and 1,739 on aspirin-based DAPT. After 1:1 matching, 306 patients remained in each group.
At 1-year follow-up, the findings were as follows:
Thus, indobufen-based DAPT provides an effective and well-tolerated alternative to traditional aspirin-based therapy in elderly patients after PCI. The results reinforce the growing role of personalized antiplatelet strategies, especially in populations vulnerable to aspirin-triggered adverse effects.
BMC Cardiovascular Disorders
Indobufen versus aspirin after percutaneous coronary intervention in elderly patients with acute coronary syndrome
BMC Cardiovascular Disorders
Comments (0)